

VO TRANSLATIONSKONTROLLE

Helmut Dolznig, Teil 1

2017

Signaltransduktion zur Translation
Regulation der Zellgröße


Unterlagen unter:

<http://www.meduniwien.ac.at/hp/medizinische-genetik/studium-lehre/externe-lehre/>

Helmut Dolznig
Inst. für Med. Genetik
MedUniWien,
Waehringer Strasse 10


Tel 40160-56502 | email helmut.dolznig@meduniwien.ac.at

Upstream Signalling




Translation verbraucht viel Energie

Translation




braucht 20-25% der gesamten zellulären Energie

Multiple Regulation der Translationsrate




1. Regulation der Translation über Wachstumsfaktoren
2. Regulation über die Nährstoffverfügbarkeit
3. Regulation durch den Energiezustand der Zelle
4. Regulation durch Stress

Upstream Signalling of Translation: Players



“Complete” mTOR pathway




mTOR Signaling in Growth Control and Disease


Mathieu Laplante^{1,2,3,*} and David M. Sabatini^{1,2,3,*}

Cell 149, April 13, 2012


“Complete” mTOR pathway



Biological Processes





Upstream Signalling of Translation: Key Players




PI3K


Phosphoinositid-3-Kinase = Lipidkinase




PTEN






PKB: PIP₃-PH domain Interaktion




Protein Kinase B / AKT




PKB: PIP₃-PH domain Interaktion




Plextrin homology (PH) domain




PKB Aktivierung




PKB/Akt Targets




PKB = Ser/Thr Kinase




PKB/Akt Targets



mTOR I



**Mammalian (mechanistic) Target Of Rapamycin
290 kD protein
befindet sich in einem rießigen Multiproteinkomplex (1,5-2MDa)**




Rapamycin bindet an FKBP12, ermöglicht erst die Bindung (an FRB) und Inhibierung von mTOR

**Ser/Thr Kinase in vitro: P 4EBP, S6K
assoziierte Kinasen**

Crystal structure: mTORΔN–mLST8–ATP γ S-Mg complex


mTOR kinase structure, mechanism and regulation

Haijuan Yang¹, Derek G. Rudge¹, Joseph D. Koos¹, Bhamini Vaidalingam¹, Hyo J. Yang¹ & Nikola P. Pavletich^{1,2}
9 MAY 2013 | VOL 497 | NATURE | 217



mTOR II

Rapamycin: aus *Streptomyces hygroscopicus*
Antimycoticum, Immunosuppressiva, Tumormedikamente




mTOR III: physiologische Effekte


mTOR

Cell growth
Proliferation
Differentiation
Migration
Survival
Autophagy

mTOR IV: Target pathways




mTOR V: mTORC1 (mTOR complex 1)



Raptor regulatory associated protein of m**TOR**
mLST8 adaptor protein


mTOR VI: mTORC2 (mTOR complex 2)



Rictor rapamycin insensitive companion of m**TOR**

**Kontrolliert Actin-Zytoskelett Dynamik, Metabolismus, Survival
Rapamycin UNABHÄNGIG**

mTORC1 and mTORC2



mTORC1

- mTOR** Serine/threonine kinase
- raptor** Scaffold protein regulating the assembly, localization, and substrate binding of mTORC1
- pras40** mTORC1 inhibitor
- deptor** mTOR inhibitor
- mLST8** Unknown function, its loss does not affect mTORC1 activity towards known substrates
- tti1** Scaffolding proteins regulating the assembly and the stability of mTORC1
- tel2**

mTORC2


- mTOR** Serine/threonine kinase
- riktor** Scaffold protein regulating the assembly and substrate binding of mTORC2
- mSin1** Scaffold protein regulating the assembly of mTORC2 and its interaction with SGK1
- protor 1/2** Protor1 increases mTORC2-mediated activation of SGK1
- deptor** mTOR inhibitor
- mLST8** Unknown function, essential for mTORC2 activity
- tti1** Scaffolding proteins regulating the assembly and the stability of mTORC2
- tel2**

mTOR Signaling in Growth Control and Disease


Mathieu Laplante^{1,2,3,*} and David M. Sabatini^{1,2,3,*}

Cell 149, April 13, 2012



mTORC1 and mTORC2




mTOR VII: 48S Translations-Initiations-Komplex



mTOR VIII: mTORC1 P von S6K und 4E-BP



mTOR IX: upstream regulation TSC1+2




Tsc1+2: Tuberousclerosis 1+2 (Hamartin+Tuberin)
mutiert in bestimmten gutartigen Tumoren (Hamartome) im Menschen

TSC1/2 heterodimer, TSC2 ist ein GAP (GTPase activating protein) und aktiviert Rheb

Protein Synthese nicht “all oder none” reguliert durch mTOR

mTOR unabhängige pathways (rapamycin resistant),
in Herzmuskelzellen 50% d. Proteinsynthese aufrecht unter Rapamycin


S6 Kinase I



2 Gene mit je 2 Splicevarianten (mammals)

multiple P sites

**p70 S6K1(cs), p85 S6K1(n)
p54 S6K2(n), p56 S6K2(n)**




P S6 (ribosomales Protein, rpS6, mit 18S rRNA assoziiert 1x per 40S),

Hypothese: S6P aktiviert Translation


volle Aktivierung von S6K braucht AA+Glucose +Insulin (GF) (absolut mTOR abhängig)

S6 Kinase II




C-terminal residues: **P** (durch ERK) ermöglicht erst Zugang für folgende **P**:

- Thr389 durch mTOR
- Thr229 durch PDK1




alle Aktivierungsstimuli Rapamycin sensitiv (d.h. mTORC1 abhängig)

S6 Kinase III: Substrate




S6 Kinase III: Substrat rpS6



S235, S236, S240, S244, S247

S6 Kinase IV: Substrat rpS6

~~P-S6 aktiviert die Translation von 5' TOP-RNAs:~~ = FALSCH
ribosmale Proteine, Proteine der Translationsmaschinerie...




5' TOP-RNAs

= translationell reprimiert in Zellzyklus arrest, AS starvation
Translationell aktiviert bei Proliferationsinduktion und AS Zugabe


Experimente in Mäusen haben gezeigt, dass die P von S6 nichts an der Translation von 5' TOP RNAs ändert (rpS6^{-/-} Mäuse mit S6^{P-/-} knock in)

eIF4B als Target von S6K




**Verstärkt die Translation von mRNAs
mit langen, strukturierten 5' UTRs** (noch nicht 100% bewiesen)

eEF2 als Target von S6K



eIF4E-BP I



4EBP

eIF4E binding protein, translationeller Repressor


3 Isoformen:

4E-BP1, 4E-BP2, 4E-BP3

multiple **P** (7x) an Thr, Ser streng hierarchisch
zuerst **P** am N-terminus, dann Mitte , zuletzt C-terminus
(durch mTOR und ERK)

elf4E-BP II

AS, Insulin, WF



P 2 Aufgaben:

- Dissoziation von 4E
- Verhinderung der Wiederbindung

AA (v.a. Leucin) beeinflussen 4EBP P: keine im Medium: 4EBP deP
Zugabe von AA P von 4EBP
nur bei bestimmten Zelltypen: ovary, embryonic kidney cells

AA (precursor für Proteinsynthese) + Energiequelle (Prot.synthese: ~25% cell. Energie)

1. Regulation der Translation über Wachstumsfaktoren
2. Regulation über die Nährstoffverfügbarkeit
3. Regulation durch den Energiezustand der Zelle
4. Regulation durch Stress

Nutrients

Starvation beeinflußt Translation

Protein Synthese:


- AA als precursor
- metabolische Energie

einige Komponenten der Translationsmaschinerie direkt beeinflußt von Nährstoffstatus
(erst seit einigen Jahren bekannt)

Initiation


Elongation

Phosphorylierung der kleinen ribosomalen Untereinheit



Nutrients

(b)




TRENDS in Molecular Medicine

RAG GTPasen notwendig für mTORC1 Aktivierung

Molekularer UND Schalter: wenn Growth Factor signaling an **UND AS** vorhanden dann mTORC Aktivierung


Nutrients




RAG GTPasen notwendig für mTORC1 Aktivierung

Molekularer UND Schalter: wenn Growth Factor signaling an **UND** AS vorhanden dann mTORC Aktivierung

elf2



AS Sensing



Extracellular Sensor

AA also regulate (repress) autophagy, e.g. in the liver
a non-cell-permeant leucine analogue could still inhibit autophagy
->extracellular leucine

plasma membrane amino acid sensor (Ssy1p) in yeast no homolog in mammals so far


Intracellular Sensor

mTOR may be regulated by intracellular amino acid levels
(C.G. Proud unpublished data)

- (a) injection of leucine into Xenopus oocytes activated TOR signalling, P S6K
- (b) alteration of intracellular amino acid levels affect mTOR signalling

1. Regulation der Translation über Wachstumsfaktoren
2. Regulation über die Nährstoffverfügbarkeit
3. **Regulation durch den Energiezustand der Zelle**
4. Regulation durch Stress

Energiezustand



1. Regulation der Translation über Wachstumsfaktoren
2. Regulation über die Nährstoffverfügbarkeit
3. Regulation durch den Energiezustand der Zelle
4. Regulation durch Stress


- Hypoxie
- Osmotischer Stress
- ROS
- DNA damage
- Strahlung (UV+Ionisierende)
- Viren

schalten Translation ab

DNA damage

- p53 dependent
- TSC2 and PTEN upregulation (PI3K Akt pathway deactivation)
- AMPK activation

Hypoxia



Zusammenfassung

➤ **Translation ist ein stark energieverbrauchender Vorgang**
1/4 der gesamten zellulären Energie gebraucht

➤ **Translationsrate ist von Wachstumsfaktoren, Energiezustand der Zell, Nährstoffverfügbarkeit (AS) und zellulärem Stress abhängig**

Wachstumsfaktoren induzieren Translation
Stress, niedriger Energiegehalt und Nährstoffengpass reduzieren Translation

➤ **Zentraler Pathway: PI3K – Akt/PKB – mTOR - S6K / 4E-BP**

➤ **Die Regulation der Translationsrate erfolgt vorwiegend über die Translationsinitiation**
eIF4E – 4E-BP; eIF4B; eIF2

➤ **Aber auch über Elongation**
eEF2

➤ **mTOR: zentrales Molekül, Integration von vielen extrazellulären und intrazellulären Inputs**
Sensor für AS Status, Energiestatus, Wachstumsfaktoren , Stress

Literatur

Averous J, Proud. When translation meets transformation: **the mTOR story.**
Oncogene. 2006 Oct 16;25(48):6423-35.

Mamane Y, Petroulakis E, LeBacquer O, Sonenberg. **mTOR, translation initiation and cancer.**
Oncogene. 2006 Oct 16;25(48):6416-22.

Corradetti MN, Guan KL. **Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?**
Oncogene. 2006 Oct 16;25(48):6347-60.

Crino PB, Nathanson KL, Henske EP. **The tuberous sclerosis complex.**
N Engl J Med. 2006 Sep 28;355(13):1345-56.

Ruvinsky I, Meyuhas O. **Ribosomal protein S6 phosphorylation: from protein synthesis to cell size.**
Trends Biochem Sci. 2006 Jun;31(6):342-8. Epub 2006 May 6.

Mayer C, Grummt I. **Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases.**
Oncogene. 2006 Oct 16;25(48):6384-91


Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. **Exploiting the PI3K/AKT pathway for cancer drug discovery.**
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004.

Samuels Y, Ericson K. **Oncogenic PI3K and its role in cancer.**
Curr Opin Oncol. 2006 Jan;18(1):77-82.

Scheid MP, Woodgett JR. **Unravelling the activation mechanisms of protein kinase B/Akt.**
FEBS Lett. 2003 Jul 3;546(1):108-12


Cully M, You H, Levine AJ, Mak TW. **Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.**
Nat Rev Cancer. 2006 Mar;6(3):184-92

Supplement




Wang et al, EMBOJ 20, 4370-79 (2001)

Upstream Signalling of Translation: Players




Raptor

Raptor (regulatory associated protein of tor) 150kD,
negativer Regulator von mTOR Kinase Aktivität
aber wird gebraucht für 4EBP, S6K P, scaffold protein




5' TOPs S6 Kinase Independence4




TOP mRNA translation abhängig von: AA, PI3K u. PKB
unabhängig S6K or S6P (S6K KO, S6K overexpression)

5' TOPs S6 Kinase Independence



mTOR II



mTOR II

